TBC1D3C Inhibitors
TBC1D3C inhibitors belong to a specific class of chemical compounds designed to target and modulate the activity of TBC1D3C, a protein encoded by the TBC1D3C gene. TBC1D3C, or TBC1 domain family member 3C, is a relatively recent discovery in the field of molecular biology and is part of the larger TBC1 domain family. These inhibitors have garnered significant attention in the realm of basic research and drug development due to their potential role in regulating cellular processes.
TBC1D3C is primarily involved in intracellular trafficking and membrane dynamics within cells. It plays a crucial role in the regulation of vesicle trafficking, particularly in the endocytic and exocytic pathways. Inhibition of TBC1D3C activity using specific inhibitors can alter these cellular processes, leading to potential implications in various biological contexts. Researchers have been keenly interested in studying these inhibitors to better understand the physiological functions and molecular mechanisms controlled by TBC1D3C. By targeting this protein, scientists aim to uncover its precise role in cellular homeostasis and potentially identify new avenues for intervention in diseases where abnormal vesicle trafficking plays a role. The development and refinement of TBC1D3C inhibitors hold promise for advancing our knowledge of cellular biology.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin acts as an inhibitor of phosphoinositide 3-kinases (PI3K), which can affect signaling pathways that could be related to TBC1D3C function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor, potentially impacting the same signaling cascades as Wortmannin, thus indirectly influencing TBC1D3C-regulated processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 selectively inhibits p38 MAPK, which might adjust cellular functions that TBC1D3C is involved in. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a central protein in cell growth and metabolism, potentially altering TBC1D3C's functional context. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor, potentially modifying signaling pathways that intersect with TBC1D3C's role. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 inhibits ROCK, potentially affecting cytoskeletal dynamics and related signaling that could implicate TBC1D3C. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which could modulate pathways influencing TBC1D3C activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that may affect MAPK/ERK pathway components, potentially altering TBC1D3C-related signaling. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
NF449 is a G-protein antagonist, potentially disrupting signals that could feed into TBC1D3C's pathway of action. | ||||||
GSK 690693 | 937174-76-0 | sc-363280 sc-363280A | 10 mg 50 mg | $255.00 $1071.00 | 4 | |
GSK690693 is an Akt inhibitor, which could interfere with signaling pathways where TBC1D3C may play a role. | ||||||